Kevin Lui is a Director at Stern IR and brings more than 10 years of experience in the investor relations field. Throughout the years, he has provided support to private and public companies, spanning from micro-cap to mega-cap corporations within the technology and healthcare sectors. Kevin has experience in a wide variety of therapeutic areas including autoimmune, oncology, infectious diseases, central nervous systems, digital health, and rare diseases. Additionally, he has provided support to companies on transactions including IPOs, secondary offerings, crossover rounds, SPACs, and M&A, as well as companies navigating through special situations like shareholder activism.
Prior to joining Stern IR, he served as a Senior Account Director on the investor relations team at Real Chemistry (May 2021 – November 2023). Before joining Real Chemistry, he was an Account Supervisor on the investor relations team at FINN Partners (September 2019 – April 2021). Prior to FINN Partners, Kevin was a Senior Associate in the Global Markets Intelligence division at Ipreo/IHS Market (August 2012 – September 2019) where he managed a portfolio of clients in the technology sector.
Kevin graduated from Rutgers University with a Bachelor’s of Science degree, double majoring in Finance and Management. In his free time, Kevin enjoys traveling, food adventures, golfing, and attending NBA and NFL games.
